XOMA (XOMA)
(Real Time Quote from BATS)
$26.72 USD
+0.02 (0.08%)
Updated Jun 14, 2024 10:16 AM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 41 - 60 ( 330 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q4/FY20: Acquiring Assets, Advancing Pipeline Means Business as Usual in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2020 Results; Partnered Phase 2 Trials Advance as Asset Portfolio Expands
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Expecting Strong Partner Data Catalysts and Continued Shopping in 2021; Target Increased to $56
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q3: NIS793 Triggers $25M Milestone; Multiple Value-Driving Catalysts in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Start a Study, Cash a Big Check; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials; Royalty Portfolio Coming into Focus in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
PacGrow Healthcare Conference: Day 1 - 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
1Q20 Results; Steady as She Goes Toward More Deals
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Active PoC Assets, Current Phase .2 Trials - Q4/FY19 Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2019 Results; Asset Base and Opportunities Continue to Grow
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Differentiated IL-2 Program Finds First Potential Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
XOMA Partnered Assets Featured Prominently During Novartis R-D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
3Q19 Results; Visibility Continues to Increase on Partnered Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Assets Continue to Grow in Numbers as New Business Model Is Validated Again; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Expanded Portfolio of Milestone and Royalty Bearing Assets
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L